Stockscreener 앱 받기
4.82
1.90%
0.09
전일 마감가:
$4.73
열려 있는:
$4.76
하루 거래량:
4.76M
Relative Volume:
1.02
시가총액:
$1.72B
수익:
$9.68M
순이익/손실:
$-250.64M
주가수익비율:
-3.4433
EPS:
-1.3998
순현금흐름:
$-89.83M
1주 성능:
+6.40%
1개월 성능:
+18.43%
6개월 성능:
+15.59%
1년 성능:
+223.49%
1일 변동 폭
$4.59
$4.87
1주일 범위
$4.4099
$4.90
52주 변동 폭
$1.39
$5.465
Precigen Inc Stock (PGEN) Company Profile
명칭
Precigen Inc
전화
301-556-9900
주소
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.82 | 1.72B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-15 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-03-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-05-23 | 개시 | JP Morgan | Neutral |
| 2022-11-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-25 | 개시 | Stifel | Buy |
| 2021-02-22 | 개시 | Wells Fargo | Overweight |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-05-08 | 개시 | H.C. Wainwright | Buy |
모두보기
Precigen Inc 주식(PGEN)의 최신 뉴스
PGEN: All proposals, including board elections and compensation, passed overwhelmingly without shareholder questions - TradingView
PGEN: All proposals, including board elections and compensation, passed overwhelmingly without dissent - TradingView
Precigen Inc Annual Shareholders Meeting Transcript - GuruFocus
Precigen Inc (PGEN) Institutional Confidence - TradingKey
Precigen Inc (PGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Precigen Inc (PGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Precigen Inc (PGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Precigen Inc (PGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Precigen Inc (PGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Precigen Inc (PGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Precigen Inc (PGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
H.C. Wainwright Remains a Buy on Precigen (PGEN) - Insider Monkey
5 Best Penny Stocks That Could Skyrocket in 2026 - Insider Monkey
Precigen gains 7 year FDA orphan drug exclusivity - grafa.com
Precigen receives seven-year exclusivity for rare disease drug - Investing.com UK
Precigen receives seven-year exclusivity for rare disease drug By Investing.com - Investing.com India
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging - ACCESS Newswire
Precigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside Estimate - Yahoo Finance
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares? - The Motley Fool
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices - PR Newswire
Precigen jumps after Q1 beat as Papzimeos launch momentum takes hold - MSN
Precigen (NASDAQ:PGEN) Share Price Crosses Below 200-Day Moving AverageWhat's Next? - MarketBeat
PGEN: Durable RRP therapy drives rapid uptake, with global expansion and oncology pipeline advancing - TradingView
Precigen, Inc. (PGEN) is a great momentum stock: Should you buy? - MSN
PGEN News | PRECIGEN INC (NASDAQ:PGEN) - ChartMill
Precigen, Inc.'s (NASDAQ:PGEN) Path To Profitability - Moomoo
Have Precigen Insiders Been Selling Stock? - simplywall.st
H.C. Wainwright reiterates Precigen stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Precigen stock rating on trial data By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Precigen(PGEN.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Precigen CCO Phil Tennant sells $131,985 in stock By Investing.com - Investing.com Australia
Precigen CFO Harry Thomasian Jr. sells $182,614 in stock - Investing.com UK
Precigen CEO Helen Sabzevari sells $519,930 in company stock - Investing.com UK
Precigen CEO Helen Sabzevari sells $519,930 in company stock By Investing.com - Investing.com South Africa
Precigen chief legal officer Lehr sells $127,011 in stock By Investing.com - Investing.com India
Precigen COO Rutul R Shah sells $186,185 in common stock By Investing.com - Investing.com India
Precigen chief legal officer Lehr sells $127,011 in stock - Investing.com
Precigen CFO Harry Thomasian Jr. sells $182,614 in stock By Investing.com - Investing.com South Africa
Precigen Inc (PGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):